17.11.2015 • News

Janssen Boosts Metabolism Portfolio with Hanmi Biologic

US-based drugs firm Janssen Pharmaceuticals has gained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based treatments for diabetes and obesity from Hanmi Pharmaceutical. Terms of the deal were not revealed.

The therapies include HM12525A, a biologic which is currently completing Phase 1 trials, and is expected to enter Phase 2 studies next year. It has shown evidence of improving blood glucose, body weight and insulin sensitivity.

Janssen said HM12525A has the potential to be a best-in-class therapy, allowing the company to build on its success in diabetes and strengthen its portfolio of treatments for metabolic diseases.

Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

On Demand | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.